ScreenerHero

TGTXTG Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · tgtherapeutics.com
54.27USD+4.99%Mkt Cap: 8.31B $P/E: 19.81

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationall…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap8.31B $
Enterprise Value7.37B $
Revenue (TTM)799.54M $
Gross Profit515.57M $
Net Income (TTM)447.18M $
Revenue/Share5.610 USD
Last Price54.27 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees399
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)19.81
P/E (Forward)17.05
PEG1.61
EV/EBITDA54.04
EV/Revenue9.22
P/S9.68
P/B12.29
EPS (TTM)2.68
EPS (Forward)2.96
52W Range
26.7685% of range59.30
52W High59.30 USD
52W Low26.76 USD
Profitability
Gross Margin83.66%
Oper. Margin9.02%
EBITDA Margin17.07%
Profit Margin72.56%
ROE69.01%
ROA42.06%
Growth
Revenue Growth70.30%
Earnings Growth-70.60%
Cash Flow & Leverage
Operating CF-24.77M $
CapEx (TTM)214.00K $
FCF Margin7.40%
FCF Yield0.71%
Net Debt202.19M $
Net Debt/EBITDA1.48
Balance Sheet
Debt/Equity0.39
Current Ratio4.27
Quick Ratio3.55
Book Value/Sh4.114 USD
Cash/Share3.893 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split100:5625
Split DateApr 30, 2012
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)69.71 USD
Upside (mean)+28.5%
Target Range21.00 USD – 86.00 USD
$21.00+28.5% to mean$86.00
# Analysts7
Ownership
Shares Out.153.07M
Float135.24M
Insiders7.47%
Institutions74.15%
Short Interest
Short Ratio13.8d
Short % Float27.68%
Short % Out.19.15%
Shares Short29.32M
Short (prev mo.)30.17M
Technical
SMA 5052.69 (+3.0%)
SMA 20037.73 (+43.9%)
Beta1.67
S&P 52W Chg18.16%
Avg Vol (30d)2.17M
Avg Vol (10d)1.70M
Technical Indicators
RSI (14)59.1
MACD-0.4173
MACD Signal-0.6347
MACD Hist.+0.2173
BB Upper57.16 USD
BB Middle51.29 USD
BB Lower45.41 USD
BB Width22.91%
ATR (14)2.500 USD
Vol Ratio (20d)2.45x